Finnish company Aplagon secures €7M in funding to advance clinical trials for thrombo-inflammatory diseases

Aplagon is a clinical-stage biopharmaceutical company dedicated to developing therapeutics for thromboinflammatory diseases, addressing critical unmet medical needs in vascular medicine.